{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:04:09Z","timestamp":1789070649131,"version":"build-2803163510"},"reference-count":126,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Cutaneous T\u2010cell lymphomas (CTCLs) have a chronic, relapsing course, and the most common subtypes are mycosis fungoides and S\u00e9zary syndrome. The disease causes visible skin alterations and can also cause alopecia, pruritus and pain, all of which can impact patients\u2019 health\u2010related quality of life (HRQoL). The goal of treatment is to reduce symptoms and prevent disease progression. However, treatment recommendations are often based on low levels of evidence due to the lack of well\u2010designed randomised clinical trials and treatment guidelines, and approved drugs vary considerably across different countries and regions. Currently, available treatments rarely lead to durable remissions and eventually become less effective, meaning patients often require multiple therapy changes. Skin\u2010directed therapies (SDTs) are first\u2010line treatments for early\u2010stage CTCL, whereas systemic therapies may be needed for early\u2010stage disease that does not respond to SDT or for advanced\u2010stage disease. However, patients can experience significant side\u2010effects with these treatments or may be unable to tolerate them. Hence, there is an unmet need for effective therapies with good safety profiles for the treatment of early\u2010 and late\u2010stage CTCL. Here, we review current treatment guidelines, investigational and approved treatments, the impact of CTCL on patients\u2019 HRQoL, and the treatment of pruritus.<\/jats:p>","DOI":"10.1111\/bjh.17117","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T13:14:22Z","timestamp":1603458862000},"page":"683-696","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T\u2010cell lymphoma"],"prefix":"10.1111","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-4408","authenticated-orcid":false,"given":"Julia J.","family":"Scarisbrick","sequence":"first","affiliation":[{"name":"University Hospital Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis Universit\u00e9 de Paris Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz\u2010Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Complutense Hospital 12 de Octubre Medical School Institute i+12 Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.7.854"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.06.006"},{"key":"e_1_2_9_4_1","unstructured":"NCRAS CTCL Report. [cited 2020 Sep 19]. Available from:http:\/\/www.ncin.org.uk\/view?rid=3275"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-016-0594-9"},{"key":"e_1_2_9_6_1","unstructured":"Orphanet: Classic mycosis fungoides. [cited 2020 Sep 21]. Available from:https:\/\/www.orpha.net\/consor\/cgi\u2010bin\/OC_Exp.php?Lng=GB&Expert=2584"},{"key":"e_1_2_9_7_1","unstructured":"Orphanet: S\u00e9zary syndrome. [cited 2020 Sep 21]. Available from:https:\/\/www.orpha.net\/consor\/cgi\u2010bin\/OC_Exp.php?Expert=3162"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.018"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17240"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054601"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00830.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"e_1_2_9_15_1","unstructured":"NCCN T\u2010Cell Lymphomas Guidelines. [cited 2020 Sep 19]. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t\u2010cell.pdf"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18541"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-791335"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.01.01"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25577"},{"key":"e_1_2_9_20_1","unstructured":"Nccn guidelines. [cited 2020 Sep 22]. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351346"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133"},{"key":"e_1_2_9_24_1","unstructured":"Adcetris Product Information. [cited 2020 Sep 19]. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adcetris"},{"key":"e_1_2_9_25_1","unstructured":"Brentuximab vedotin Orphan Designation. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/medicines\/human\/orphan\u2010designations\/eu311939"},{"key":"e_1_2_9_26_1","unstructured":"Ledaga EPAR Summary. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ledaga"},{"key":"e_1_2_9_27_1","unstructured":"Mogamulizumab Orphan Designation. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/medicines\/human\/orphan\u2010designations\/eu3161756"},{"key":"e_1_2_9_28_1","unstructured":"Poteligeo Product Information. [cited 2020 Sep 19]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/poteligeo\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_29_1","unstructured":"Roferon\u2010A Patient Information Leaflet. [cited 2020 Sep 19]. Available from:www.medicines.org.uk\/emc\/product\/1117"},{"key":"e_1_2_9_30_1","unstructured":"Targretin EPAR Medicine Overview. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/documents\/overview\/targretin\u2010epar\u2010medicine\u2010overview_en.pdf"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.11.02"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810601)47:11<2671::AID-CNCR2820471125>3.0.CO;2-X"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.3.423"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08992.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.3.325"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22252"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.01.012"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18089"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16021"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16447"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1793764"},{"key":"e_1_2_9_42_1","unstructured":"Adcetris Prescribing Information. [cited 2020 Sep 19]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125388s100lbl.pdf"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.01.02"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.02.019"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11127"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402610"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8065"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.017"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1492"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3221"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00382.x"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694117"},{"key":"e_1_2_9_54_1","unstructured":"NIHR Innovation Observatory Evidence Briefing.Synthetic hypericin (SGX301; VIMRxyn) for cutaneous T\u2010cell lymphoma unspecified;2017. [cited 2020 Sep 19]. Available from:www.io.nihr.ac.uk\/wp\u2010content\/uploads\/migrated_new\/10761\u2010Synthetic\u2010Hypericin.pdf"},{"key":"e_1_2_9_55_1","unstructured":"Poteligeo Prescribing Information. [cited 2020 Sep 19]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761051s000lbl.pdf"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525915"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-630335"},{"key":"e_1_2_9_58_1","unstructured":"T\u2010cell Lymphoma Forum Industry Innovations miRagen MicroRNA Oral Presentation. Cobomarsen an emerging potential treatment for patients with miR\u2010155 elevated cancers. [cited 2020 Sep 19]. Available from:www.miragen.com\/publications\/2019\/02\/T\u2010cell\u2010Lymphoma\u2010Forum\u2010Industry\u2010Innovations\u2010miRagen\u2010MicroRNA\u2010Oral\u2010Presentation.pdf"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5905"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx352"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.025"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.10.03"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2879"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20187134"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12909"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.08.033"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00260"},{"key":"e_1_2_9_70_1","unstructured":"Revlimid Prescribing Information. [cited 2020 Sep 19]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021880s049lbl.pdf"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071388"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.039"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114576"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13513"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S5009"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.706286"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.05.008"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.043"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.161"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.014"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588236"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.07.004"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30320-1"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209942"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0634-5"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10879"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.6.727"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25218"},{"key":"e_1_2_9_92_1","unstructured":"Skilarence Product Information. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/documents\/product\u2010information\/skilarence\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0658-x"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0435-2"},{"key":"e_1_2_9_95_1","unstructured":"Tecfidera Product Information. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/documents\/product\u2010information\/tecfidera\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1492122"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-4039"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11593"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_9_101_1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0959-8049(19)30595-7","article-title":"Brentuximab vedotin (BV) versus physician\u2019s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30\u2010positive cutaneous T\u2010cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study","volume":"119","author":"Scarisbrick JJ","year":"2019","journal-title":"Eur J Cancer"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18535"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S165615"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00307.x"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7539"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122778"},{"key":"e_1_2_9_108_1","unstructured":"Kyowa Kirin Press Release.Approval for Additional Indication for PTCL and CTCL of Mogamulizumab;2018. [cited 2020 Sep 19]. Available from:https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2018\/e20180821_01.html"},{"key":"e_1_2_9_109_1","unstructured":"Humanised IgG1 monoclonal antibody against human KIR3DL2 for the treatment of cutaneous T\u2010cell lymphoma Orphan Designation. [cited 2020 Sep 19]. Available from:www.ema.europa.eu\/en\/documents\/orphan\u2010designation\/eu\/3\/14\/1322\u2010public\u2010summary\u2010opinion\u2010orphan\u2010designation\u2010humanised\u2010igg1\u2010monoclonal\u2010antibody\u2010against\u2010human_en.pdf"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1456"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025999"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3171"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05188.x"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2819"},{"key":"e_1_2_9_116_1","doi-asserted-by":"crossref","unstructured":"QuaglinoP HudgensS PorcuP CowanR FlodenL TsianakasA et al.Quality of life in cutaneous T\u2010cell lymphoma subjects treated with the anti\u2010CCR4 monoclonal antobody mogamulizumab versus vorinostat: results from the Phase 3 MAVORIC Trial. HemaSphere.2018;2:85.https:\/\/doi.org\/10.1097\/HS9.0000000000000060","DOI":"10.1097\/HS9.0000000000000060"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.2196\/11302"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.12.021"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2417"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12587"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0789"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.025"},{"key":"e_1_2_9_123_1","first-page":"1140","article-title":"Substance P induction of itch\u2010associated response mediated by cutaneous NK1 tachykinin receptors in mice","volume":"286","author":"Andoh T","year":"1998","journal-title":"J Pharmacol Exp Therap"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3194-8"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16128"},{"key":"e_1_2_9_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-004-0802-8"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5597"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:24:28Z","timestamp":1693653868000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":126,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bjh.17117"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17117","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738888521.793579727","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"2020-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}